Business Context and Reporting Period
Company: Gossamer Bio, Inc. (GOSS)
Filing Type: Form 8-K (Current Report)
Date of Report: July 1, 2026
Event: Regulation FD Disclosure regarding the initial conversion rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and the initial exercise price for associated Purchase Warrants.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or liquidity metrics. It discloses specific terms related to the company's debt instruments:
- Instrument: 7.50% Convertible Senior Secured First Lien Notes due 2030.
- Initial Conversion Rate: 5,347.5936 shares of common stock per $1,000 principal amount.
- Implied Conversion Price: Approximately $0.19 per share.
- Warrant Exercise Price: $0.34 per whole share of common stock.
Material Changes
The filing announces the finalization of the initial conversion rate and warrant exercise price for the 2030 Convertible Notes. No comparative financial data or changes versus prior periods are provided in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies beyond the disclosure of the debt instrument terms. The primary purpose is to disclose the specific conversion mechanics to the market.
Investor Verification Checklist
- Verify the total principal amount outstanding for the 2030 Convertible Notes to assess potential dilution.
- Confirm the current trading price of GOSS common stock relative to the $0.19 conversion price and $0.34 warrant exercise price.
- Review the full text of the press release (Exhibit 99.1) for any additional covenants or conditions attached to the conversion.
- Check subsequent filings for updates on the company's liquidity position given the secured nature of the notes.